ATE555794T1 - Heilmittel gegen hepatitis - Google Patents

Heilmittel gegen hepatitis

Info

Publication number
ATE555794T1
ATE555794T1 AT01904385T AT01904385T ATE555794T1 AT E555794 T1 ATE555794 T1 AT E555794T1 AT 01904385 T AT01904385 T AT 01904385T AT 01904385 T AT01904385 T AT 01904385T AT E555794 T1 ATE555794 T1 AT E555794T1
Authority
AT
Austria
Prior art keywords
hepatitis
remedies
virus
present
cell
Prior art date
Application number
AT01904385T
Other languages
English (en)
Inventor
Seima Itami
Tatsurou Shibui
Makoto Seki
Yoshihisa Yotsumoto
Yoshiharu Matsuura
Tatsuo Miyamura
Original Assignee
Mitsubishi Tanabe Pharma Corp
Jp Agency Of Nat Inst Of Infectious Deseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp, Jp Agency Of Nat Inst Of Infectious Deseases filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ATE555794T1 publication Critical patent/ATE555794T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
AT01904385T 2000-02-14 2001-02-13 Heilmittel gegen hepatitis ATE555794T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000034906 2000-02-14
PCT/JP2001/000967 WO2001058459A1 (fr) 2000-02-14 2001-02-13 Remedes contre l'hepatite c

Publications (1)

Publication Number Publication Date
ATE555794T1 true ATE555794T1 (de) 2012-05-15

Family

ID=18559171

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01904385T ATE555794T1 (de) 2000-02-14 2001-02-13 Heilmittel gegen hepatitis

Country Status (8)

Country Link
US (1) US7101551B2 (de)
EP (1) EP1256348B1 (de)
KR (1) KR20020091093A (de)
CN (1) CN100391469C (de)
AT (1) ATE555794T1 (de)
AU (1) AU2001232267A1 (de)
BR (1) BR0108499A (de)
WO (1) WO2001058459A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
WO2005021792A1 (ja) * 2003-08-28 2005-03-10 Dainippon Sumitomo Pharma Co., Ltd. 抗ｃｄ８１抗体を有効成分として含有する炎症性腸疾患の予防または治療剤
JP4654418B2 (ja) * 2004-03-31 2011-03-23 独立行政法人産業技術総合研究所 上皮系細胞増殖促進剤
EP2468774A3 (de) 2005-04-18 2013-01-02 Amgen Research (Munich) GmbH Antikörperneutralisierer des menschlichen Granulozyten-Makrophagenkolonie-stimulierenden Faktors
PL2274331T3 (pl) * 2008-05-02 2014-04-30 Novartis Ag Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie
EP2494046B1 (de) 2009-10-30 2018-09-12 Novartis AG Unterseitig bindende universelle fibronectin-typ-iii-domänenbibliotheken
US20130129676A1 (en) 2010-05-25 2013-05-23 Universite De Strasbourg Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
CN103249833B (zh) * 2010-12-06 2016-06-29 大日本住友制药株式会社 人单克隆抗体
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024157A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of host targeting agents for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
EP2914289B1 (de) 2012-10-31 2019-05-22 Takeda GmbH Lyophilisierte formulierung mit einer gm-csf-neutralisierenden verbindung
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
ES2928000T3 (es) * 2014-06-06 2022-11-14 Memorial Sloan Kettering Cancer Center Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
BR112021000727A2 (pt) * 2018-07-20 2021-04-13 Surface Oncology, Inc. Composições anti-cd112r e métodos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
JPH08510240A (ja) * 1993-05-12 1996-10-29 カイロン コーポレイション Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
CN1044384C (zh) * 1994-08-25 1999-07-28 中国药品生物制品检定所 抗丙型肝炎病毒抗原单克隆抗体细胞株建立及其单克隆抗体
CN1072482C (zh) * 1996-11-08 2001-10-10 山东医科大学 低分子肝素脂质体喷胶剂及制备工艺
JP4198882B2 (ja) * 1997-10-06 2008-12-17 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｃ型肝炎レセプタータンパク質ｃｄ８１
AU5285899A (en) 1998-07-21 2000-02-14 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
WO2000026418A1 (en) 1998-11-05 2000-05-11 The Board Of Trustees Of Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
US20040038392A1 (en) 2000-06-08 2004-02-26 Tatsurou Shibui Expression vector enabling screening of cells with high expression of recombinant protein, transformant with high expression of recombinant protein and utilization thereof

Also Published As

Publication number Publication date
BR0108499A (pt) 2003-03-11
CN100391469C (zh) 2008-06-04
WO2001058459A1 (fr) 2001-08-16
EP1256348A4 (de) 2005-07-27
AU2001232267A1 (en) 2001-08-20
EP1256348A1 (de) 2002-11-13
US20030157132A1 (en) 2003-08-21
KR20020091093A (ko) 2002-12-05
US7101551B2 (en) 2006-09-05
CN1423561A (zh) 2003-06-11
EP1256348B1 (de) 2012-05-02

Similar Documents

Publication Publication Date Title
ATE555794T1 (de) Heilmittel gegen hepatitis
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
PT1169339E (pt) Peptidos macrociclicos activos contra o virus da hepatite c
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
EA200700243A1 (ru) Способы лечения гепатита с
EP1673385A4 (de) Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
GEP20104956B (en) Compounds for inhibiting hepatitis c viral replication and use thereof
ATE269321T1 (de) Arzneimittel gegen virale erkrankungen
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
WO2009039246A3 (en) Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection
ID27457A (id) Komposisi untuk pengobatan hiv dan infeksi virus lainnya
EP1730167A4 (de) Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
WO2010047830A3 (en) Agents for hcv treatment
BR0305259A (pt) Inibidores de hcv ns5b polimerase
ECSP056181A (es) Compuestos Inhibidores de la Hepatitis C
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
LU92748I2 (fr) Virus de la diarrhée virale bovine atténué 2 (bvdv-2)
WO2003055896A3 (en) Anti-viral 7-deaza l-nucleosides
DK1387681T3 (da) Anvendelse af castanosperinderivater til behandling af hepatitis C
PT1299395E (pt) Oxazinoquinolonas uteis para o tratamento de infeccoes provocadas por virus
WO2002062959A3 (en) Hepatitis b virus treatment
NO20033829L (no) Virusdrepende preparater